Drug profile

The FDA adverse-event record for Oclacitinib

708 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Oclacitinib. See the species affected, top reactions, and outcomes below.

708
adverse-event reports
6.8%
death-coded share
Dog
most-reported species
109
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
708
Total Reports
48
Deaths Reported
6.8%
Death Rate

Active Ingredients

Oclacitinib

Administration Routes

OralUnknownIntragastric

Species Affected

Dog 655
Unknown 50
Cat 2
Horse 1

Most Affected Breeds

Retriever - Labrador 64
Unknown 56
Shih Tzu 40
Crossbred Canine/dog 33
Shepherd Dog - German 30
Chihuahua 27
Pit Bull 25
Beagle 22
Terrier - Yorkshire 22
Retriever - Golden 22

Most Reported Reactions

Vomiting 109
Lack of efficacy - NOS 80
Diarrhoea 76
Lethargy (see also Central nervous system depression in 'Neurological') 57
Not eating 42
Pruritus 36
Anorexia 35
Lethargy (see also Central nervous system depression in Neurological) 35
Behavioural disorder NOS 34
Elevated blood urea nitrogen (BUN) 33
Elevated serum alkaline phosphatase (SAP) 33
Decreased appetite 32

Outcome Breakdown

Outcome Unknown
290 (44.1%)
Recovered/Normal
194 (29.5%)
Ongoing
105 (16.0%)
Euthanized
29 (4.4%)
Recovered with Sequela
21 (3.2%)
Died
19 (2.9%)

Oclacitinib Adverse Event Insights

708 reports name Oclacitinib; 48 recorded a death outcome (6.8% of reported events, not a population-level mortality rate). Active ingredient: Oclacitinib. Administration routes: Oral, Unknown, Intragastric.

By species: Dog (655 reports), Unknown (50 reports), Cat (2 reports). By breed: Retriever - Labrador (64), Unknown (56), Shih Tzu (40).

Leading clinical signs: Vomiting (109), Lack of efficacy - NOS (80), Diarrhoea (76), Lethargy (see also Central nervous system depression in 'Neurological') (57). Outcome, 658 coded reports: Outcome Unknown leads at 44.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.